

**Drug Utilization Review (DUR) Meeting Minutes
September 14, 2009**

Members Present: Patricia Churchill, Norman Byers, Carrie Sorenson, Greg Pfister, Kim Krohn, Jeffrey Hostetter, John Savageau, Carlotta McCleary, David Clinkenbeard, Steve Irsfeld, Russ Sobotta, James Carlson, Todd Twogood

Members Absent: Cheryl Huber, Leann Ness

Medicaid Pharmacy Department: Brendan Joyce, Gary Betting

HID Staff Present: Candace Rieth

Chair, J. Hostetter called the meeting to order at 1:00 pm. Chair, J. Hostetter asked for a motion to approve the minutes from the June meeting. P. Churchill moved that the minutes be approved and T. Twogood seconded the motion. Chair, J. Hostetter called for a voice vote to approve the minutes. The motion passed with no audible dissent.

New Members

Russell Sobotta, representing PhRMA; James Carlson, representing GPhA; and David Clinkenbeard, representing the ND Medical Association, are the new members that have been appointed to the Board. Chair, J. Hostetter asked that all DUR Board members introduce themselves to the new members.

Budget Update

B. Joyce had no new information to present regarding the budget.

Hemophilia Review

The Board reviewed utilization of factors in the Medicaid population. Specialists in the field, Pharmacist Mark Plencner and Physician Nathan Kobrinsky, participated in the discussion via teleconference. There was no public comment. T. Twogood made a motion that a prior authorization is placed on factors with criteria that includes:

1. Proof of an accredited specialist involved in therapy
2. Date of last appointment with specialist
3. Specialist's contact information

G. Pfister seconded the motion. A prior authorization form and criteria will be presented at the December meeting.

Uloric Second Review

At the June meeting a motion was made to prior authorize Uloric. This is the second review. G. Pfister made a motion to include the dose of allopurinol (greater than or equal to 300mg) that should be tried before requesting a prior authorization for Uloric. C. Sorenson seconded the motion. There was no public comment. Chair, J. Hostetter called for a voice vote on the amendment. Motion passed with no audible dissent. Chair, J. Hostetter called for a voice vote on the original motion. Motion passed with no audible dissent.

Moxatag Second Review

At the June meeting a motion was made to place Moxatag on prior authorization. This is the second review. There was no public comment. Chair, J. Hostetter called for a voice vote on the original motion. Motion passed with no audible dissent.

Targeted Immune Modulators Second Review

At the June meeting a motion was made to place targeted immune modulators on prior authorization. This is the second review. There was no public comment. Chair, J. Hostetter called for a voice vote on the original motion. Motion passed with no audible dissent.

Yearly PA Review

The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Dispense as Written (DAW), Amrix, Xenical, Zanaflex capsules, and Ketek forms and criteria were reviewed. S. Irsfeld made a motion to include an informational bullet on the DAW form that states “not allowed for drugs with authorized generics”. N. Byers seconded the motion. Chair, J. Hostetter called for a voice vote on the motion. Motion passed with no audible dissent.

Sancuso Review

C. Rieth reviewed Sancuso with Board members. There was no public comment. N. Byers made a motion to place Sancuso on prior authorization. P. Churchill seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

Relistor Review

C. Rieth reviewed Relistor with Board members. There was no public comment. J. Hostetter made a motion to place Relistor on prior authorization with the following criteria:

1. Unable to tolerate oral medications *or*
2. Failed two oral medications

N. Byers seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

Nuvigil Review

B. Joyce reviewed Nuvigil with Board members. There was no public comment. P. Churchill made a motion to place Nuvigil on prior authorization. G. Pfister seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

Nucynta Review

C. Rieth reviewed Nucynta with the Board members. There was no public comment. N. Byers made a motion to place Nucynta on prior authorization. G. Pfister seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

Criteria Recommendations

The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. J. Savageau moved to approve the new criteria and N. Byers seconded the motion. Chair, J. Hostetter called for a voice vote. The motion passed with no audible dissent.

The next DUR board meeting will be held December 7, 2009. N. Byers made a motion to adjourn the meeting. T. Twogood seconded. The motion passed with no audible dissent. Chair J. Hostetter adjourned the meeting at 2:45 pm.